File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Behind the rosiglitazone controversy

TitleBehind the rosiglitazone controversy
Authors
KeywordsAcarbose
Adrenomedullin
Metformin
Pioglitazone
Rosiglitazone
Issue Date2010
PublisherExpert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/loi/ecp
Citation
Expert Review Of Clinical Pharmacology, 2010, v. 3 n. 6, p. 723-725 How to Cite?
AbstractOn 23 September 2010, the US FDA and the EMA issued statements announcing their response to data implicating the use of the antidiabetes drug rosiglitazone (Avandia®, GlaxoSmithKline plc, London, UK) with an increased risk of cardiovascular events, including acute myocardial infarction and stroke. The EMA has implemented an immediate suspension of the drug, meaning that it will no longer be available in Europe. The FDA stopped short of a total suspension, but has stated that use of the drug should be restricted to patients with Type 2 diabetes who cannot control their diabetes with other medications. In this article, Bernard Cheung of the Expert Review of Clinical Pharmacology Editorial Advisory Board gives his insight into the matter. Cheung graduated from the University of Cambridge (UK) and received a PhD in Clinical Pharmacology in 1995. He then joined the University of Hong Kong as the Lecturer in Clinical Pharmacology and later became Professor. He held the Chair in Clinical Pharmacology and Therapeutics at the University of Birmingham (UK) in 2007–2009. Cheung’s main research interest is in cardiovascular diseases and risk factors, including hypertension and the metabolic syndrome. He works on vasoactive peptides, such as adrenomedullin and urotensin II. He is also interested in clinical trials, meta-analyses, drug utilization and medication safety and is the Chief Editor of the Open Diabetes Journal, and an Executive Editor of the British Journal of Clinical Pharmacology.
Persistent Identifierhttp://hdl.handle.net/10722/129297
ISSN
2015 Impact Factor: 2.488
2015 SCImago Journal Rankings: 0.794
References

 

DC FieldValueLanguage
dc.contributor.authorCheung, BMYen_HK
dc.date.accessioned2010-12-23T08:34:50Z-
dc.date.available2010-12-23T08:34:50Z-
dc.date.issued2010en_HK
dc.identifier.citationExpert Review Of Clinical Pharmacology, 2010, v. 3 n. 6, p. 723-725en_HK
dc.identifier.issn1751-2433en_HK
dc.identifier.urihttp://hdl.handle.net/10722/129297-
dc.description.abstractOn 23 September 2010, the US FDA and the EMA issued statements announcing their response to data implicating the use of the antidiabetes drug rosiglitazone (Avandia®, GlaxoSmithKline plc, London, UK) with an increased risk of cardiovascular events, including acute myocardial infarction and stroke. The EMA has implemented an immediate suspension of the drug, meaning that it will no longer be available in Europe. The FDA stopped short of a total suspension, but has stated that use of the drug should be restricted to patients with Type 2 diabetes who cannot control their diabetes with other medications. In this article, Bernard Cheung of the Expert Review of Clinical Pharmacology Editorial Advisory Board gives his insight into the matter. Cheung graduated from the University of Cambridge (UK) and received a PhD in Clinical Pharmacology in 1995. He then joined the University of Hong Kong as the Lecturer in Clinical Pharmacology and later became Professor. He held the Chair in Clinical Pharmacology and Therapeutics at the University of Birmingham (UK) in 2007–2009. Cheung’s main research interest is in cardiovascular diseases and risk factors, including hypertension and the metabolic syndrome. He works on vasoactive peptides, such as adrenomedullin and urotensin II. He is also interested in clinical trials, meta-analyses, drug utilization and medication safety and is the Chief Editor of the Open Diabetes Journal, and an Executive Editor of the British Journal of Clinical Pharmacology.-
dc.languageengen_US
dc.publisherExpert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/loi/ecpen_HK
dc.relation.ispartofExpert Review of Clinical Pharmacologyen_HK
dc.subjectAcarbose-
dc.subjectAdrenomedullin-
dc.subjectMetformin-
dc.subjectPioglitazone-
dc.subjectRosiglitazone-
dc.titleBehind the rosiglitazone controversyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1751-2433&volume=3&issue=6&spage=723&epage=725&date=2010&atitle=Behind+the+rosiglitazone+controversy-
dc.identifier.emailCheung, BMY:mycheung@hku.hken_HK
dc.identifier.authorityCheung, BMY=rp01321en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1586/ecp.10.126en_HK
dc.identifier.scopuseid_2-s2.0-78649381418en_HK
dc.identifier.hkuros183466en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-78649381418&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume3en_HK
dc.identifier.issue6en_HK
dc.identifier.spage723en_HK
dc.identifier.epage725en_HK
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridCheung, BMY=7103294806en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats